[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Rinsho Ketsueki
; 53(1): 78-82, 2012 Jan.
Article
en Ja
| MEDLINE
| ID: mdl-22374528
ABSTRACT
We report two patients who achieved a marked improvement of hematopoiesis with the use of deferasirox (DSX) for transfusional iron overload. Case 1 is an 81-year-old male who was diagnosed with primary myelofibrosis in July, 2007. He required regular red blood cell (RBC) transfusion of 4 units/month when he was started on DSX treatment in June, 2009. Four months after the treatment, he became transfusion independent, and has maintained hemoglobin levels of around 13 g/dl until today. Case 2 is a 70-year-old female with acute myeloid leukemia with myelodysplasia-related changes. She had been on RBC transfusion of 4 units/month when she was started on DSX treatment in January, 2010. Two months after the treatment, she became transfusion-independent, and 5 months after treatment, blast cells completely disappeared in the peripheral blood, together with normalization of white blood cell and neutrophil counts. Achieving durable transfusion-independency and normalization of white blood cell count and differential with a single use of DSX is a very rare event. Prospective accumulation of more patients and research to understand the mechanism underlying these effects are clearly warranted.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Triazoles
/
Benzoatos
/
Síndromes Mielodisplásicos
/
Leucemia Mieloide Aguda
/
Quelantes del Hierro
/
Sobrecarga de Hierro
/
Mielofibrosis Primaria
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
Ja
Revista:
Rinsho Ketsueki
Año:
2012
Tipo del documento:
Article